» Articles » PMID: 18045110

Roles of HIV-1 Env Variable Regions in Viral Neutralization and Vaccine Development

Overview
Journal Curr HIV Res
Date 2007 Nov 30
PMID 18045110
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

A major focus of HIV-1 vaccine development has been directed towards a limited number of broadly conserved epitopes in the Envelope (Env) proteins that are sensitive neutralization targets in many primary isolates. However, evidence suggests that these epitopes are poorly immunogenic; similar antibodies are rarely produced by infected subjects, nor are they induced by various immunogens designed to express these epitopes. On the other hand, the major variable domains of Env are highly immunogenic; antibodies against these regions are common in sera of infected patients and easily generated upon immunization. Although these epitopes are extremely sensitive neutralization targets in some laboratory strains and primary isolates, the neutralization range of antibodies against these sites is limited. This review describes potent neutralization epitopes located in the variable regions of Env and discusses the bases for the limited neutralization breadth of antibodies against these targets. Strategies are discussed for using available information to design immunogens capable of exploiting the potential of these regions as vaccine targets.

Citing Articles

Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.

Spurrier B, Sampson J, Gorny M, Zolla-Pazner S, Kong X J Virol. 2014; 88(8):4100-12.

PMID: 24478429 PMC: 3993739. DOI: 10.1128/JVI.03153-13.


Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.

ORourke S, Schweighardt B, Phung P, Mesa K, Vollrath A, Tatsuno G J Virol. 2012; 86(22):12105-14.

PMID: 22933284 PMC: 3486483. DOI: 10.1128/JVI.01352-12.


Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.

Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker J J Virol. 2012; 86(22):12115-28.

PMID: 22933274 PMC: 3486499. DOI: 10.1128/JVI.01632-12.


Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape.

Bar K, Tsao C, Iyer S, Decker J, Yang Y, Bonsignori M PLoS Pathog. 2012; 8(5):e1002721.

PMID: 22693447 PMC: 3364956. DOI: 10.1371/journal.ppat.1002721.


HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Schader S, Colby-Germinario S, Quashie P, Oliveira M, Ibanescu R, Moisi D Antimicrob Agents Chemother. 2012; 56(8):4257-67.

PMID: 22615295 PMC: 3421599. DOI: 10.1128/AAC.00639-12.